

Thermo Fisher Scientific announces expansion of bioanalytical laboratory services in Europe

23 September 2024 | News

Expansion will add up to 140 highly skilled scientists and laboratory support professionals



The PPD clinical research business of US-based Thermo Fisher Scientific has announced the expansion of its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden, that will serve pharmaceutical and biotech customers with advanced laboratory services and leading-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide.

The new 29,000-square-foot laboratory will be adjacent to the Gothenburg strategic research and development site of the global pharmaceutical company AstraZeneca, which has been instrumental in the development of GoCo Health Innovation City.

Steptura, a joint real estate company among Next Step Group, Balder and Vectura Fastigheter, designed the life science and global research cluster in Sweden to attract researchers and entrepreneurs from around the world and to accelerate health innovation.

The PPD clinical research business will expand its bioanalytical capabilities to include comprehensive and full-service solutions, encompassing both small and large molecules, biomarkers and novel modalities. Service offerings will include a wide range of advanced technologies and methodologies, such as cell-based assays, chromatography, flow cytometry, immunochemistry and molecular genomics.

The expansion will add up to 140 highly skilled scientists and laboratory support professionals, ranging from entry-level bench positions to general manager. The new lab, which is expected to be completed in the fourth quarter of 2025, will be equipped with state-of-the-art instrumentation, enabling a wide range of GLP-compliant bioanalytical capabilities.